Your browser doesn't support javascript.
loading
Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector.
Bresk, C Anika; Hofer, Tamara; Wilmschen, Sarah; Krismer, Marina; Beierfuß, Anja; Effantin, Grégory; Weissenhorn, Winfried; Hogan, Michael J; Jordan, Andrea P O; Gelman, Rebecca S; Montefiori, David C; Liao, Hua-Xin; Schmitz, Joern E; Haynes, Barton F; von Laer, Dorothee; Kimpel, Janine.
Afiliação
  • Bresk CA; Division of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria. ANIKA.BRESK@I-MED.AC.AT.
  • Hofer T; Division of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria. tamara.hofer@i-med.ac.at.
  • Wilmschen S; Christian Doppler Laboratory for Viral Immunotherapy of Cancer, Medical University of Innsbruck, 6020 Innsbruck, Austria. tamara.hofer@i-med.ac.at.
  • Krismer M; Division of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria. sarah.wilmschen@i-med.ac.at.
  • Beierfuß A; Division of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria. marina.krismer@gmail.com.
  • Effantin G; Central Laboratory Animal Facility, Medical University of Innsbruck, 6020 Innsbruck, Austria. Anja.Beierfuss@i-med.ac.at.
  • Weissenhorn W; Institut de Biologie Structurale (IBS), CNRS, CEA, Université Grenoble Alpes, 38044 Grenoble, France. gregory.effantin@ibs.fr.
  • Hogan MJ; Institut de Biologie Structurale (IBS), CNRS, CEA, Université Grenoble Alpes, 38044 Grenoble, France. winfried.weissenhorn@ibs.fr.
  • Jordan APO; Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. hoganm@email.chop.edu.
  • Gelman RS; Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. andreado@pennmedicine.upenn.edu.
  • Montefiori DC; Dana-Farber Cancer Institute, Harvard Medical School and Harvard School of Public Health, Boston, MA 02215, USA. gelman@jimmy.harvard.edu.
  • Liao HX; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. david.montefiori@duke.edu.
  • Schmitz JE; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. l.liao@duke.edu.
  • Haynes BF; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA. joern.e.schmitz@gmail.com.
  • von Laer D; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. barton.haynes@duke.edu.
  • Kimpel J; Division of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria. Dorothee.von-Laer@i-med.ac.at.
Viruses ; 11(2)2019 02 15.
Article em En | MEDLINE | ID: mdl-30769947
ABSTRACT
A chimeric vesicular stomatitis virus with the glycoprotein of the lymphocytic choriomeningitis virus, VSV-GP, is a potent viral vaccine vector that overcomes several of the limitations of wild-type VSV. Here, we evaluated the potential of VSV-GP as an HIV vaccine vector. We introduced genes for different variants of the HIV-1 envelope protein Env, i.e., secreted or membrane-anchored, intact or mutated furin cleavage site or different C-termini, into the genome of VSV-GP. We found that the addition of the Env antigen did not attenuate VSV-GP replication. All HIV-1 Env variants were expressed in VSV-GP infected cells and some were incorporated very efficiently into VSV-GP particles. Crucial epitopes for binding of broadly neutralizing antibodies against HIV-1 such as MPER (membrane-proximal external region), CD4 binding site, V1V2 and V3 loop were present on the surface of VSV-GP-Env particles. Binding of quaternary antibodies indicated a trimeric structure of VSV-GP incorporated Env. We detected high HIV-1 antibody titers in mice and showed that vectors expressing membrane-anchored Env elicited higher antibody titers than vectors that secreted Envs. In rabbits, Tier 1A HIV-1 neutralizing antibodies were detectable after prime immunization and titers further increased after boosting with a second immunization. Taken together, VSV-GP-Env is a promising vector vaccine against HIV-1 infection since this vector permits incorporation of native monomeric and/or trimeric HIV-1 Env into a viral membrane.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / HIV-1 / Vacinas contra a AIDS / Produtos do Gene env do Vírus da Imunodeficiência Humana / Vetores Genéticos Limite: Animals Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / HIV-1 / Vacinas contra a AIDS / Produtos do Gene env do Vírus da Imunodeficiência Humana / Vetores Genéticos Limite: Animals Idioma: En Ano de publicação: 2019 Tipo de documento: Article